{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T01:47:59Z","timestamp":1773452879285,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.semarthrit.2020.02.014","type":"journal-article","created":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T11:06:15Z","timestamp":1582974375000},"page":"1414-1420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical characteristics associated with drug-free sustained remission in patients with rheumatoid arthritis: Data from Korean Intensive Management of Early Rheumatoid Arthritis (KIMERA)"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3465-2181","authenticated-orcid":false,"given":"Seung Min","family":"Jung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Yoon","family":"Pyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason Jungsik","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo-Kon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Beom","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semarthrit.2020.02.014_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.02.014_bib0002","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.02.014_bib0003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2020.02.014_bib0004","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1136\/ard.2010.134684","article-title":"State-of-the-art: rheumatoid arthritis","volume":"69","author":"McInnes","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.02.014_bib0005","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the Eular recommendations for management of rheumatoid arthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 6","key":"10.1016\/j.semarthrit.2020.02.014_bib0006","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kes278","article-title":"Evolution of treatment for rheumatoid arthritis","volume":"51","author":"Upchurch","year":"2012","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.02.014_bib0007","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1136\/ard.2008.105577","article-title":"Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"69","author":"O'Mahony","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2020.02.014_bib0008","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1002\/art.24661","article-title":"Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts","volume":"60","author":"van der Woude","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.02.014_bib0009","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/03009740903042394","article-title":"Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up","volume":"39","author":"Tiippana-Kinnunen","year":"2010","journal-title":"Scand J Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.02.014_bib0010","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1136\/annrheumdis-2014-207080","article-title":"Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms","volume":"75","author":"Ajeganova","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.semarthrit.2020.02.014_bib0011","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1007\/s10067-016-3413-8","article-title":"Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission","volume":"35","author":"El Miedany","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.02.014_bib0012","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1136\/annrheumdis-2014-206439","article-title":"Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled retro study","volume":"75","author":"Haschka","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.02.014_bib0013","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/annrheumdis-2017-211375","article-title":"Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: improved study","volume":"77","author":"Akdemir","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"19","key":"10.1016\/j.semarthrit.2020.02.014_bib0014","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1316133","article-title":"Sustained remission with etanercept tapering in early rheumatoid arthritis","volume":"371","author":"Emery","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.02.014_bib0015","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/annrheumdis-2013-204632","article-title":"Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the certain double-blind, randomised, placebo-controlled trial","volume":"74","author":"Smolen","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.semarthrit.2020.02.014_bib0016","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/ard.2009.121491","article-title":"Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study","volume":"69","author":"Tanaka","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"9870","key":"10.1016\/j.semarthrit.2020.02.014_bib0017","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0140-6736(12)61811-X","article-title":"Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial","volume":"381","author":"Smolen","year":"2013","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.semarthrit.2020.02.014_bib0018","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/rheumatology\/kex315","article-title":"Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?","volume":"56","author":"Ibrahim","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.02.014_bib0019","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/annrheumdis-2014-206696","volume":"75","author":"Fautrel","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.02.014_bib0020","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13075-019-1937-4","article-title":"The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis","volume":"21","author":"Tanaka","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.02.014_bib0021","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/annrheumdis-2013-204016","article-title":"Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the honor study","volume":"74","author":"Tanaka","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2020.02.014_bib0022","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/ard.2009.117341","article-title":"Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?","volume":"69","author":"Saleem","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.02.014_bib0023","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/art.11481","article-title":"Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission","volume":"50","author":"Molenaar","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.02.014_bib0024","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/ard.2006.057497","article-title":"Radiological damage in patients with rheumatoid arthritis on sustained remission","volume":"66","author":"Cohen","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.02.014_bib0025","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1002\/art.23945","article-title":"An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis","volume":"58","author":"Brown","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.semarthrit.2020.02.014_bib0026","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/rheumatology\/kex084","article-title":"Grade and location of power Doppler are predictive of damage progression in rheumatoid arthritis patients in clinical remission by anti-tumour necrosis factor alpha","volume":"56","author":"Raffeiner","year":"2017","journal-title":"Rheumatology"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220300676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220300676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:04:50Z","timestamp":1758733490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017220300676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0049017220300676"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.02.014","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical characteristics associated with drug-free sustained remission in patients with rheumatoid arthritis: Data from Korean Intensive Management of Early Rheumatoid Arthritis (KIMERA)","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}